In the fall of 2020, Unite Life Sciences brought together the below experts to address some of the industry's most pressing questions around designing clinical trials. We have adaptive design, but what else can be considered in diverse approaches to treat cancer? What have we learned about what else might be considered to augment with real world evidence and other data sets that could be valuable to understand the safety and effectiveness of a new molecule? How can industry be “better” at designing trials to utilize resources in the best way possible?
Speakers:
Fill out the form to start watching one of our most dynamic sessions from October's virtual forum, Rethinking Clinical Trials in Oncology, and be sure to RSVP for the spring 2021 forum.
Real-world data (RWD) is increasingly being used to facilitate and enhance clinical research in oncology. Opportunities for using RWD in oncology trials include assessing protocol feasibility by overlaying trial eligibility criteria onto a RWD source, identifying patients from RWD sources for inclusion in external control arms, and using RWD to augment data collection in long-term follow-up studies following gene therapy trials. However, it is easy to underestimate the challenges that arise in implementation.
Take a look at one of our dynamic sessions from October's virtual forum, Rethinking Clinical Trials in Oncology, where Syneos' Ann Collins, Vice President, Clinical Development, and David Thompson, Senior Vice President, Real World Research, discuss the opportunities and challenges for RWD in oncology trials.
Be sure to RSVP for the May 19, 2021 forum.